Staging of renal cell carcinoma: Current concepts.
Staging of renal cell carcinoma: Current concepts.
复制标题
DOI：
10.4103/0970-1591.57906
复制
发表时间：
2009-10
期刊：
影响因子：
--
通讯作者：
Breda A
中科院分区：
文献类型：
--
作者：
Lam JS;Klatte T;Breda A
肾细胞癌（RCC）手术治疗后提供预后信息的最重要和最广泛使用的系统是目前的肿瘤、淋巴结和转移（TNM）分期系统。一个准确和临床上有用的分期系统是一个重要的工具，用于为患者提供有关预后的咨询，选择治疗方式，并确定临床试验的资格。过去几年发表的数据导致了重大争议，是否需要进一步修订，以及是否可以通过引入新的，更准确的预测预后因素进行改进。分期系统也随着对RCC肿瘤生物学的理解的增加而发展。分子肿瘤生物标志物有望通过提供比传统临床变量更有效的预后能力来彻底改变RCC的分期。本文将探讨TNM分期系统的组成部分，目前的分期模式，包括全面综合分期系统，预测诺模图，并介绍了肾癌的分子分期的概念。
The most important and widely utilized system for providing prognostic information following surgical management for renal cell carcinoma (RCC) is currently the tumor, nodes, and metastasis (TNM) staging system. An accurate and clinically useful staging system is an essential tool used to provide patients with counseling regarding prognosis, select treatment modalities, and determining eligibility for clinical trials. Data published over the last few years has led to significant controversies as to whether further revisions are needed and whether improvements can be made with the introduction of new, more accurate predictive prognostic factors. Staging systems have also evolved with an increase in the understanding of RCC tumor biology. Molecular tumor biomarkers are expected to revolutionize the staging of RCC by providing more effective prognostic ability over traditional clinical variables alone. This review will examine the components of the TNM staging system, current staging modalities including comprehensive integrated staging systems, and predictive nomograms, and introduce the concept of molecular staging for RCC.